Coordination of COVID-19 Research

Leadership at the University of Pittsburgh and UPMC has designated the Clinical and Translational Science Institute as the central hub for collecting information and providing resources related to COVID-19 research studies (see full announcement below). This directive applies to any and all research studies that require HRPO (IRB) approval.

If your research team at the University of Pittsburgh or UPMC is 1) currently conducting COVID-19 research; 2) planning to implement COVID-19 research; or 3) amending a current research study to include COVID-19 measures, please click on the survey link below to submit a description of your work and identify any resources (e.g., funding, collaborations, lab, regulatory, recruitment) that may be needed. For general questions, please email covid19research@pitt.edu.

Our goal is to remove barriers and expedite your research as we face this unprecedented health threat.

Following your submission, a research facilitator will quickly evaluate and respond to your needs. (Even if you do not require assistance with your study, please submit your information and we will catalog it in our database.)

GO TO SURVEY

Dear Colleagues,

Research teams at the University of Pittsburgh and UPMC have mobilized to plan and implement clinical trials and clinical research studies related to COVID-19. Given the rapidity of the spread of disease, timely and efficient implementation of studies are critical to their success.

To support and facilitate these studies, we are mobilizing the Clinical and Translational Science Institute (CTSI), to help coordinate resources, expertise, research tools, and lab capabilities.

CTSI will catalogue every Pitt or UPMC COVID-19 related research protocol involving human subjects and/or associated biosamples, electronic health record and other data. This will enable Pitt and UPMC to:

  • Identify collaborative opportunities among study teams
  • Coordinate with HRPO to streamline regulatory submissions
  • Assess researchers’ needs
  • Provide research tools (e.g., electronic consents)
  • Leverage expertise (e.g., study design)
  • Link to institutional resources (e.g., biobanking, Health Record Research Request (R3))
  • Harmonize data elements across studies
  • Help provide integration with national and international research efforts

We are asking all principal investigators planning or conducting COVID-19 related studies to submit a brief description of their proposal at https://www.covid-19research.pitt.edu/.

Finally, funding opportunities are available from multiple sources. You can find details on this link same as noted above.

Please send requests for additional information, or send ideas that are not yet formed into a defined project to covid19research@pitt.edu.

Arthur S. Levine
Senior Vice Chancellor for the Health Sciences

Rob A. Rutenbar
Senior Vice Chancellor for Research

Steven D. Shapiro
Chief Medical and Science Officer

COVID-19 Federal Funding Opportunities

SPONSOR PROGRAM FUNDING DEADLINE
Clinical & Translational Science Institute
COVID-19 Pilot Grant Program $200,000 (total funding available) 4/3/2020
Centers for Disease Control (CDC) Applied Research to Address The Coronavirus (COVID-19) Emerging Public Health Emergency $10,000,000 (total funding available) 3/25/2020

National Institutes of Health (NIH)

NIAID, NIGMS

Notice of Special Interest (NOSI) Regarding the Availability of Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus (2019-nCoV) Not limited 2/6/2021
(rolling basis)
National Science Foundation (NSF) Dear Colleague Letter on the Coronavirus Disease 2019 (COVID-19) $200,000 Check with program officers

National Institutes of Health (NIH)

NCI, NCCIH, NHGRI, NIAID, NICHD, NIDDK, NIEHS, NIGMS, NIMHD, NIBIB

Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional) Not limited See Emergency Notice of Special Interest by IC

National Institutes of Health (NIH)

NIDA

Notice of Special Interest (NOSI) Regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus $100,000 direct costs/year 3/31/2021
(rolling basis)
Medical CBRN Defense Consortium Request for Information (RFI) - CoV Pandemic Response Not limited 5/31/2020
(rolling basis)
Amazon Web Services (AWS) AWS Diagnostic Development Iniative (DDI) Up to $20M available 6/30/2020
LifeArc LifeArc COVID-19 Fund £10M (total funding available) 4/6/2020
Biomedical Advanced Research and Development Authority (BARDA) Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA) Negotiated after white paper stage 10/31/2020

National Institutes of Health (NIH)

NCATS

Notice of Special Interest (NOSI): Clinical and Translational Science Award (CTSA) Program Applications to Address 2019 Novel Coronavirus (COVID-19) Public Heath Need Must reflect your needs 7/9/2021
American Heart Association (AHA) AHA Rapid Response Grant COVID-19 and Its Cardiovascular Impact Up to $100,000 4/6/2020
Medical Technology Enterprise Consortium (MTEC)
Development of Treatments for COVID-19 Up to $500,000 4/8/2020
Department of Health and Human Services
Hospital Associations COVID-19 Preparedness and Response Activities   3/30/2020
Pitt Office of Sponsored Programs
The Office of Sponsored Programs provides real-time, updated information on all funding opportunities for research on COVID-19 Various Various